ETFs & MarketsBasicCytoSorbents Targets 2026 Breakeven: What it Means for MedTech ETFs
CytoSorbents has officially outlined its financial and regulatory roadmap, targeting operating cash flow breakeven by the second half of 2026. This strategic update comes as the company prepares for the DrugSorb-ATR de novo submission, now scheduled for late 2026 or early 2027.
Published 17 hours ago
Read more →